a b s t r a c t CM2 is the second membrane protein of influenza C virus and possesses a conserved motif for Nglycosylation. To investigate the role(s) of CM2 glycosylation in the virus replication, we generated rN11A, a recombinant influenza C virus lacking the glycosylation site. The rN11A virus grew less efficiently than the wild-type (WT) virus, although the biochemical characteristics of the mutant CM2 were similar to those of authentic CM2. The amount of the genome (GFP-vRNA) in the CM2-N11A-virus-like particles (VLPs) was 13% of that found in WT-VLPs. The incoming GFP-vRNA was less efficiently transported to the nucleus in CM2-N11A-VLP-infected cells than WT-VLP-infected cells, leading to the reduced reporter gene expression in CM2-N11A-VLP-infected cells. Thus the glycosylation of CM2 is required for efficient replication of influenza C virus, and the obtained findings confirmed and extended the previous observation that CM2 is involved in the genome packaging and uncoating processes.
Introduction
Influenza C virus has seven single-stranded RNA segments of negative polarity and these segments encode the nine virus proteins (Palese and Shaw, 2007) . The RNA segment 6 (M gene) of C/Ann Arbor/1/50 (AA/50) is 1180 nucleotides in length (Muraki et al., 2007) and contains a single open reading frame (positions 26-1150) that could encode a polypeptide (P42) of 374 amino acids (Hongo et al., 1994; Muraki and Hongo, 2010) . The predominant mRNA transcript of this RNA segment lacks a region from nucleotides 754 to 981 and encodes a 242-amino acid matrix (M1) protein (Hongo et al., 1994; Yamashita et al., 1988) . Unspliced mRNA of the gene is first translated into P42, and then it is cleaved by signal peptidase at an internal cleavage site, generating M1 0 and CM2, which are composed of the N-terminal 259 amino acids and the C-terminal 115 amino acids of P42, respectively (Hongo et al., 1994 (Hongo et al., , 1999 Pekosz and Lamb, 1998) .
CM2 is a type III integral membrane protein that is oriented in membranes with a 23-amino-acid N-terminal extracellular domain, a 23-amino-acid transmembrane domain and a 69-amino-acid Cterminal cytoplasmic domain Pekosz and Lamb, 1997) . It forms disulfide-linked dimers and tetramers, and is posttranslationally modified by palmitoylation and phosphorylation (Hongo et al., 1994; Li et al., 2001; Tada et al., 1998) . It is also modified by N-glycosylation on an asparagine at residue 11, and, as a result, three forms of CM2 with different electrophoretic mobilities (CM2o, CM2a, and CM2b) are detected in infected cells Pekosz and Lamb, 1997) . A mannose-rich oligosaccharide core is added to unglycosylated CM2o (Mr E16,000) to form CM2a (Mr E18,000), and the maturation of the carbohydrate chain from the high mannose type to the complex type converts CM2a into CM2b (Mr 22,000-30,000), the latter of which is modified by addition of polylactosaminoglycan.
To clarify the role(s) of CM2 in influenza C virus replication cycle, several experiments have been carried out. Electrophysiological analyses showed that CM2 forms a voltage-activated ion channel permeable to Cl - . When co-expressed with a pH-sensitive hemagglutinin (HA) of influenza A virus, the CM2 protein has a capacity to reduce the acidity of the exocytic pathway (Bé takova and Hay, 2007) . The CM2 protein expressed from cDNA in 293T cells could alter cytoplasmic pH (Stewart and Pekosz, 2012) . A recent study using CM2-deficient VLPs suggested the involvement of CM2 in the genome packaging and uncoating processes , although the role(s) of CM2 in the context of virus replication remains to be clarified.
Analyses of a number of CM2 mutants expressed in COS-1 and HeLa cells revealed the positions of the amino acids involved in the posttranslational modifications Pekosz and Lamb, 1997) : an asparagine at residue 11 is an N-glycosylation site, cysteines at residue 1, 6 and 20 are involved in disulfide bond formation, a cysteine at residue 65 is palmitoylated, and serines at residue 78, 103, 108 are phosphorylation sites. Evidence was obtained that the N-glycosylation is not required for either the formation of disulfide-linked multimers or transport to the cell surface (Pekosz and Lamb, 1997) and that none of dimer-and tetramer-formation, palmitoylation or phosphorylation is essential for the transport of CM2 to the cell surface . Recently, we reported that the defect in palmitoylation of CM2 did not affect transport and maturation of HEF, NP and M1 as well as CM2 in virus-infected cells, and palmitoylation of CM2 was dispensable to influenza C virus replication . Given these findings, posttranslational modifications of CM2 do not appear to be involved in virus replication, although all of the amino acids are conserved among influenza C virus strains examined to date (Matsuzaki et al., 2003; Tada et al., 1997) . In the present study, therefore, we examined the effect of another posttranslational modification, N-glycosylation, on the influenza C virus replication.
Results

Synthesis of CM2 in recombinant-infected cells
To investigate the effect of CM2 glycosylation on the influenza C virus replication, we generated rN11A, a recombinant influenza C virus lacking the CM2 glycosylation site. To first examine whether the CM2 protein lacking glycosylation is synthesized in rN11A-infected cells, HMV-II cells infected with rWT or rN11A at an MOI of 5 PFU/cell were subjected to radioimmunoprecipitation. As shown in Fig. 1A , CM2 was synthesized in both rWT-and rN11Ainfected cells, and CM2 synthesized in the rN11A-infected cells was confirmed to be non-glycosylated form of CM2, since CM2 in the rN11A-infected cells had the same gel mobility as CM2 treated with N-glycanase in the rWT-infected cells. Furthermore, CM2 in the rN11A-infected cells was not apparently degraded after 120-min chase (Fig. 1B) . Thus, the non-glycosylated CM2 synthesized in the rN11A-infected cells was stable.
P42, encoded by a collinear transcript of the M gene, is cleaved by signal peptidase to generate M1 0 and CM2 (Hongo et al., 1999; Pekosz and Lamb, 1998) . Fig. 1A showed that the band intensity of P42 in rN11A-infected cells increased compared with that in rWTinfected cells just after pulse-labeling (0 min). We therefore measured and compared the band intensities of M1, P42 (P44) and CM2. The ratio of M1 to (P42 þCM2) just after pulse-labeling was 0.8: 1.0 in rN11A-infected cells, which was equivalent to that ]methionine for 20 min at 26 h p.i. and chased for 120 min. The cell lysates were immunoprecipitated with anti-CM2 serum, and the immunoprecipitated proteins were digested with ( þ ) or without ( À ) N-glycanase for 16 h at 37 1C and analyzed by SDS-PAGE. (B) The infected cells were pulse-labeled with [ 35 S]methionine at 26 h p.i. and chased for the indicated periods (min). The lysates were immunoprecipitated with either anti-M1 MAb (L2) or anti-CM2 serum and analyzed by SDS-PAGE. (C) Growth kinetics of recombinant viruses. HMV-II cells were infected with rWT or rN11A at an MOI of 0.001, and then incubated for up to 120 h. The virus yields in the culture media at the indicated times were titrated using LLC-MK 2 cells. Data are expressed as the mean 7standard deviation (SD) in three independent experiments. All comparisons between groups were statistically evaluated ( n p o0.05; nn p o 0.01). (D) HMV-II cells infected with rWT or rT13A at an MOI of 0.001 were incubated for up to 120 h. The virus yields in the culture media at 72, 96 and 120 h p.i. were titrated, and the titers from three independent experiments are shown as open circles (rWT) and closed triangles (rT13A). All comparisons between the groups were statistically evaluated ( nn p o0.01). (E) Pulse-chase experiments of virus-infected cells. The infected cells were pulse-labeled with [ 35 S]methionine at 26 h p.i. and chased for the indicated periods (min). The lysates were immunoprecipitated with MAbs against HEF (J14), NP (H27) or M1 (L2) and analyzed by SDS-PAGE.
in rWT-infected cells (0.7: 1.0) ( Fig. 1B) . Thus, no significant difference was observed in the ratio of the amount of M1 to that of (P42þ CM2) just after pulse-labeling between rWT-and rN11Ainfected cells. In contrast, the ratio of CM2 to P42 in rN11Ainfected cells (1.0: 0.8) was much greater than that in rWTinfected cells (1.0:0.08) ( Fig. 1B) . Taken together, these results indicate that the amount of P42 synthesized in rN11A-infected cells is virtually identical to that in rWT-infected cells and suggest that the conversion of P42 into CM2 is delayed in rN11Ainfected cells.
Growth kinetics of recombinants
We next compared growth kinetics of the recombinant viruses. The rWT or rN11A virus was infected to HMV-II cells at an MOI of 0.001 PFU/cell and incubated at 33 1C for 120 h in the presence of trypsin (20 mg/ml). The viruses in the culture media at 12-120 h p.i. were titrated on LLC-MK 2 cells. As a result, the rN11A virus grew less efficiently than did rWT (Fig. 1C ).
To confirm that the lack of glycosylation, not the amino acid mutation, attenuates the virus, we generated another mutant virus, rT13A, in which a threonine at residue 13 within a motif for N-glycosylation (11-NNT-13) of CM2 was mutated to alanine. We confirmed that CM2 synthesized in the rT13A-infected HMV-II cells was not glycosylated (data not shown). The growth of rT13A in HMV-II cells was examined under the condition described above, and as a result it was significantly reduced by approximately 10-times compared with that of rWT (p o0.01) ( Fig. 1D ).
Therefore, we concluded that glycosylation of CM2 appears to have some effect on the generation of infectious viruses in cultured cells, and decided to use the rN11A virus in the subsequent experiments.
Synthesis of HEF, NP and M1 in infected cells
The major virus proteins synthesized in virus-infected cells were examined. HMV-II cells infected with rWT or rN11A at an MOI of 5 PFU/cell were pulse-labeled with [ 35 S]methionine for 20 min at 26 h p.i. and chased for 60-240 min (Fig. 1E ). The cell lysates were immunoprecipitated with the MAbs against HEF (J14), NP (H27) and M1 (L2), and analyzed by SDS-PAGE. The synthesis and maturation of the HEF, NP and M1 proteins exhibited no significant differences between the rWT-and rN11A-infected cells.
Maturation and transport of CM2 in infected cells
To examine whether the lack of glycosylation of CM2 affects its multimer formation, the immunoprecipitated CM2 protein labeled with [ 35 S]methionine were treated with N-glycanase and analyzed by SDS-PAGE under non-reducing conditions ( Fig. 2A ). The bands corresponding to monomer (M), dimer (D) and tetramer (T) were detected both in the rWT-and rN11A-infected cells, although the origin of a band detected in rN11A-infected cells (0 min, indicated by triangle) is unknown. (D) Surface expression of HEF and CM2 in infected cells. The surface of the virus-infected cells was biotinylated and then the cells were lysed. The biotinylated proteins were precipitated with streptavidin-agarose. The precipitates (B) or whole cell lysates (L) were subjected to immunoblotting using anti-CM2 serum or anti-HEF MAb (S16).
Immunofluorescent analysis using anti-CM2 serum showed that the CM2 protein was expressed on the cell surface in both the rWT-and rN11A-infected cells (Fig. 2B ). Furthermore, immunofluorescence of rN11A-infected cells showed that CM2 intracellular localization was not altered by loss of glycosylation (Fig. 2C ). The amount of CM2 expressed on the rN11A-infected cell surface was comparable to that on rWT-infected cells ( Fig. 2D ), since there was no apparent difference in the ratio of biotinylated CM2 (lane B) to the whole CM2 (lane L) between rWT-and rN11Ainfected cells. In Fig. 2D , an origin of E30 kDa band in rN11Ainfected cells is unknown. Taken together, these observations indicate that glycosylation-deficient CM2 is transported appropriately to the cell surface like authentic CM2.
Analyses of recombinant virus-infected cells
To further study the difference in the growth kinetics between rWT and rN11A, a number of experiments were performed. First, the rWT-or rN11A-infected HMV-II cells were analyzed by flow cytometry using anti-HEF MAb (J14). The histogram of the infected cells showed that there were no differences in the attachment and internalization between the rWT and rN11A viruses ( Fig. 3) . Takeda et al. (2002) showed the reduced synthesis of NP by amantadine was observed in the MDCK cells infected with amantadine-sensitive influenza A virus strains at the early phase of infection. In the present study, to examine virus protein synthesis at the early phase of infection, the rWT-or rN11A-infected cells were labeled with [ 35 S]methionine for 30 min every 2 h from 2 to 24 h p.i. and the respective cell lysates were analyzed by SDS-PAGE. However, we could not detect any differences in the synthesis of NP (data not shown). Thus we could not obtain evidence for the growth difference between rWT and rN11A (Fig. 1C ) by analyzing the recombinant-infected cells.
Generation of influenza C VLPs possessing non-glycosylated CM2
The influenza C VLP generation system has been shown to be of use to study the effect of mutation(s) on the virus replication process . In the present study, therefore, we generated N11A-VLPs, VLPs possessing non-glycosylated CM2, and analyzed the VLPs, VLP-producing cells and VLP-infected cells.
Prior to the experiment, we re-evaluated the amount of pME18S/ Met-CM2-YA transfected to 293T cells since the efficiency of reporter gene transfer by the generated WT-VLPs varied according to the amount of pME18S/Met-CM2-YA. As a result, WT-VLPs generated from the 293T cells transfected with 0.0315 mg pME18S/Met-CM2-YA per 35-mm dish showed the most efficient gene transfer to HMV-II cells (data not shown).
Using the above-mentioned amount of pME18S/Met-CM2-YA or pME18S/Met-CM2-N11A, WT-VLPs or N11A-VLPs were respectively generated from the 293T cells. The amounts of the purified VLPs generated from a given number of 293T cells were quantified using Pierce 660 nm Protein Assay Kit (Thermo Fischer) according to the manufacturer's instructions. Three independent experiments showed that the relative amount ratios of WT-VLPs to N11A-VLPs were 1.0:1.03, 1.0:1.71, 1.0:1.04, which did not reach statistical significance between the two VLP populations (p ¼0.370). Therefore, we concluded that there was no difference in the efficiency of VLP formation between the two constructs.
An equal amount of the purified VLPs was analyzed by immunoblotting using MAbs against HEF, NP and M1, and anti-CM2 serum ( Fig. 4A and B ). No significant differences were observed in the amounts of HEF and M1, whereas the amounts of NP in the DCM2and N11A-VLPs were smaller than that in the WT-VLPs ( Fig. 4A ). To better quantify the amount of CM2 in WT-VLPs, the sample was treated with N-glycanase and then analyzed by Western blotting (Fig. 4B , left lane). The result showed that there was no significant difference in the amounts of CM2 incorporated between WT-VLPs and N11A-VLPs. The amounts of GFP-vRNA in the DCM2and N11A-VLPs were 3% and 13% of that in the WT-VLPs, respectively (po0.01) ( Fig. 4C ). Thus we concluded that the CM2 glycosylation is involved in the genome packaging process, since the amounts of virus components (HEF, NP, M1, CM2 and GFP-vRNA) in N11A-VLP-producing 293T cells were comparable to those in the WT-VLP-producing cells (data not shown).
Reporter gene expression in VLP-infected HMV-II cells
CM2 has been shown to be involved in the uncoating process . To examine whether the glycosylation of CM2 affects the uncoating process, we analyzed the VLP-infected HMV-II cells. First, attachment and internalization of the VLPs were examined. As described previously , an equal number of WT-and N11A-VLPs, which was calculated based on the hemagglutinin units of the VLP preparations, was added to HMV-II cells, followed by flow cytometry. The histograms showed Fig. 3 . Flow cytometry of HMV-II cells infected with recombinant viruses. HMV-II cells infected with recombinant viruses were incubated at 4 1C for 30 min and then incubated at 33 1C for a further 120 min. The cells were reacted with anti-HEF MAb (J14) and analyzed by flow cytometry. The histogram from mock-infected cells is shown as a shaded area. Vertical and horizontal lines indicate the number of cells and fluorescence intensities, respectively. that the attachment and internalization of the N11A-VLPs occurred as efficiently as that of the WT-VLPs (Fig. 5A ).
Next, reporter gene expression in the VLP-infected cells was examined. HMV-II cells were infected with VLPs so that the copy number of GFP-vRNA included in WT-VLPs was equal to that in N11A-VLPs, i.e. VLP preparations containing eight times as many N11A-VLPs as WT-VLPs were infected. As a result, the GFP expression level in the N11A-VLP-infected cells was reduced compared with that in the WT-VLP-infected cells (Fig. 5B) .
To quantify the reporter gene expression, WT-and N11A-VLPs containing luciferase (Luc)-vRNA were generated and infected to HMV-II cells; eight times as many N11A-VLPs as WT-VLPs were used for infection. At 48 h p.i., the Luc activity in N11A-VLP-infected cells was 15.674.2% of that in WT-VLP-infected cells (po0.01). Furthermore, three independent experiments showed that the Luc activity in N11A-VLP-infected cells was constantly lower than those in WT-VLP-infected cells at 3-12 h p.i. (po0.01) (Fig. 5C ). Taken together, these findings highly suggest that the uncoating of the N11A-VLPs occurs inefficiently than that of WT-VLP.
GFP-vRNA in VLP-infected HMV-II cells
Upon analysis of the roles of CM2 using the VLP system , the localization of the incoming GFP-vRNA in the VLP-infected cells at the early phase of infection was examined by in situ hybridization, in order to obtain evidence for the impaired uncoating of DCM2-VLP. However, the location (nuclear or cytoplasm) of GFP-vRNA in the WT-VLP-infected HMV-II cells could not be clearly observed due to the high background signals (data not shown). In the present study, we quantified the incoming GFP-vRNA transported to the nucleus of VLP-infected cells as reported previously .
As shown in Fig. 5D , there was no significant difference in the total copy number of GFP-vRNA in the cells just after the incubation for 30 min at 4 1C between WT-and N11A-VLP-infected cells, indicating that an equal amount of GFP-vRNAs was used for infection. After incubation at 33 1C for 60 min, the copy number of GFP-vRNA in the nuclear fraction of WT-VLP-infected cells significantly increased (po0.05), whereas that of N11A-VLP-infected cells did not change. Furthermore, after the 60 min-incubation, a significant difference in the copy numbers in the nuclear fraction was observed between WT-VLP-and N11A-VLP-infected cells (po0.05). These findings are consistent with the idea that GFP-vRNA uncoated from the WT-VLPs was efficiently transported to the nucleus whereas the transport of the gene occurred less efficiently in the N11A-VLP-infected cells. Taking these observations, we concluded that glycosylation of CM2 is involved in the uncoating process.
Discussion
To investigate the role(s) of CM2 in virus replication, we generated recombinant influenza C viruses lacking CM2. However, no infectious recombinants have been rescued to date (data not shown). We then focused on the posttranslational modification sites of CM2, and generated rCM2-C65A, a recombinant influenza C virus lacking CM2 palmitoylation . The growth of the rCM2-C65A virus was virtually identical to that of the parental virus. As a result, we could not clarify the role(s) of CM2 using the recombinant lacking CM2 palmitoylation. In the present study, therefore, we examined the effect of N-glycosylation of CM2 on the influenza C virus replication. A recombinant influenza C virus lacking glycosylation of CM2 (rN11A) was successfully rescued, and we showed that rN11A was attenuated compared with rWT ( Fig. 1C) , indicating that the glycosylation of CM2 is required for the efficient production of progeny viruses. Furthermore, a series of analyses using N11A-VLPs enabled us to demonstrate that the CM2 glycosylation is involved in the genome packaging and uncoating processes ( Figs. 4 and 5) . Thus, the findings obtained in the present study confirmed and extended the previous observation that CM2 is involved in the packaging and uncoating , since we could provide evidence for the growth difference of the mutant virus for the first time.
Calnexin/calreticulin are involved in quality control of glycoproteins in the ER. The chaperons interact with newly synthesized glycoproteins, promote their proper folding and assembly in the ER, and the polypeptides properly folded and oligomerized are transported to the Golgi apparatus (reviewed in Parodi, 2000) . The influenza A virus HA protein is controlled by calnexin/calreticulin (Hebert et al., 1996 (Hebert et al., , 1997 and the influenza C virus HEF lacking a glycosylation site is defective in transport and trimerization , whereas the influenza B virus NB lacking glycosylation was properly expressed on the cell surface (Williams and Lamb, 1988 ). In the present study, we showed that CM2 synthesized in rN11A-infected cells was properly oligomerized and transported to the cell surface (Fig. 2) , which is consistent with the previous observation that glycosylation is not required for the transport of CM2 (Pekosz and Lamb, 1997) . Thus, it is less likely that calnexin/calreticulin are involved in CM2 folding and oligomerization. A mutation(s) within the sequences downstream of the signal peptide in a given membrane protein can affect its protein processing, such as the US11 in human cytomegalovirus (Rehm et al., 2001 ) and a coat protein of filamentous phage M13 (Russel and Model, 1981) . In the present study, we could provide evidence that a mutation introduced in CM2 caused a decrease in the cleavage efficiency of the precursor protein, P42. As mentioned in the Results Section, a comparison of the amounts of M1, P42 (P44) and CM2 between rWT-and rN11A-infected cells showed that the conversion of P42 into CM2 was delayed in rN11A-infected cells, suggesting that P42 is cleaved less efficiently by the lack of glycosylation. However, it is unlikely that the inefficient cleavage of P42 in the rN11A-infected cells affects the virus growth, since the synthesis (Fig. 1A) and surface expression ( Fig. 2B and D) of CM2 occurred appropriately.
A comparison of the amounts of GFP-vRNA between WT-and N11A-VLPs revealed that the glycosylation of CM2 affected genome packaging (Fig. 4) . To investigate whether the difference in the packaging efficiency can be observed in the case of recombinants, HMV-II cells were infected with rWT and rN11A at an MOI 5 and progeny viruses generated from the cells were examined. The yield of the rWT virus was 2-3 times as high as that of the rN11A virus, but there was no significant difference in the growth kinetics (data not shown). This finding suggests that a subtle difference in the virus yield shown in the high-MOI-infection experiment resulted in a considerable difference in the multi-step growth experiment (Fig. 1C) , and indicates that it is difficult to clearly demonstrate the difference in packaging efficiency using recombinant viruses.
The reduced packaging efficiency of N11A-VLPs may be related to the structure and/or function of CM2. In the present study, no unexpected mutations were found in the mutant M gene (data not shown). Furthermore, based on our previous observations Tada et al., 1998, Muraki and Hay, personal communication) , it is likely that both palmitoylation and phosphorylation occurs on glycosylation-deficient CM2 molecules. We therefore hypothesized that the loss of glycosylation affects the structure of cytoplasmic region of the CM2 tetrameric molecule, e.g. distance between each CM2 monomer, leading to the reduced packaging efficiency. Alternatively, the reduced chloride ion channel activity of the glycosylation-deficient CM2 may also be taken into account if the activity is linked to the genome packaging . Takeda et al. (2002) reported that NP protein synthesis at the early phase of infection occurred less efficiently in the cells infected with influenza A viruses in which the uncoating process was impaired. In the present study, to detect the difference in virus protein synthesis at the early phase of infection, synthesis of the NP protein in rWT-and rN11A-infected cells was examined, but no difference was observed between the two cell populations (see Results). Therefore, the Luc activity in the VLP-infected cells HMV-II cells infected with WT-or N11A-VLPs were treated as described in the legend of Fig. 3. (B) Mock-, WT-and N11A-VLP-infected HMV-II cells were superinfected with AA/50, and then incubated for 48 h, followed by observation in a fluorescent microscope (magnification, Â 100). (C) HMV-II cells infected with VLPs containing luciferase-vRNA (see text) were lysed at the indicated periods after infection, and the luciferase activity in the lysate was quantified. The luciferase activity detected in the WT-VLP-infected cell lysate at 12 h p.i is expressed as 100. (D) HMV-II cells infected with WT-or N11A-VLPs were incubated at 4 1C for 30 min and then transferred to 33 1C, followed by incubation for a further 60 min. The cells were divided into cytoplasmic and nuclear fractions, and the GFP-vRNA contained in the fractions was quantified by real-time PCR. The vertical line indicates the copy number of GFP-vRNA and the copy number in the cytoplasmic fraction of WT-VLP-infected cells at 4 1C was used for normalization. The data obtained from four independent experiments are shown as the means7SD. All comparisons between groups were statistically evaluated by using a paired t test ( n po0.05; nn po0.01; NS, not significant). was examined. The activities in the N11A-VLP infected cells was constantly lower than those in WT-VLP-infected cells (Fig. 5C ), a finding suggesting that the uncoating of N11A-VLPs occurred less efficiently than did WT-VLPs. Moreover, the fact that the incoming GFP-vRNA was transported to the nucleus less efficiently in N11A-VLP-infected cells than WT-VLP-infected cells (Fig. 5D ) supports the idea that the uncoating of N11A-VLPs is impaired.
The glycosylation-deficient CM2 has recently shown to possess the ability to reduce pH of cytoplasm (Stewart and Pekosz, 2012) although it remains unknown whether the activity of the glycosylation-deficient CM2 is similar to that of authentic CM2. A number of studies showed that glycosylation of channel proteins directly influences the gating characteristics and pH sensitivity of the channel (Freeman et al., 2000; Montpetit et al., 2009; Wirkner et al., 2008) . Therefore, the possibility can be proposed that the greater ability of authentic CM2 to reduce pH of the virion interior than the glycosylation-deficient CM2 would be required for efficient uncoating.
Materials and methods
Cells and antibodies
293T, HMV-II, and LLC-MK 2 cells were maintained in Dulbecco modified Eagle medium with 10% fetal bovine serum, RPMI 1640 medium with 10% calf serum, and minimal essential medium with 5% fetal bovine serum and 5% calf serum, respectively Nishimura et al., 1989) . Monoclonal antibodies (MAbs) against the HEF (J14, D37, S16), NP (H27, H31), and M1 (L2) proteins of AA/50, and anti-CM2 serum were reported previously (Hongo et al., 1994; Sugawara et al., 1991 Sugawara et al., , 1993 .
Plasmids
The Pol I plasmids for the expression of virus RNAs (vRNAs) of AA/50 (pPolI/PB2, pPolI/PB1, pPolI/P3, pPolI/HEF, pPolI/NP, pPolI/M and pPolI/NS), and the plasmids for the expression of the influenza C virus proteins (pcDNA/PB2-AA, pcDNA/PB1-AA, pcDNA/P3-AA, pME18S/HEF-AA, pCAGGS.MCS/NP-AA, pCAGGS.MCS/M1-AA, pME18S/Met-CM2-YA, pME18S/NS1-YA, and pME18S/NS2-YA) were reported previously (Muraki et al., , 2007 . The plasmid, pPolI/M-CM2-N11A, used to generate vRNA encoding M1 and nonglycosylated CM2, was generated by changing 833-AAC-835 of the M gene to 833-GCC-835, based on pPolI/M. The plasmid, pME18S/ Met-CM2-N11A, for the expression of the non-glycosylated CM2 protein, was constructed based on pPolI/M-CM2-N11A. Details of the primers and PCR protocols will be provided on request.
Generation of recombinant viruses by reverse genetics
A recombinant wild-type (rWT) virus, which has the consensus sequences of AA/50, was generated by transfecting the abovementioned 16 plasmids into 293T cells as described previously (Muraki et al., 2007) . To generate a recombinant mutant virus (rN11A), in which the asparagine at residue 11 of CM2 is mutated to alanine, the pPolI/M-CM2-N11A was transfected into 293T cells together with the other six Pol I plasmids and the nine expressing plasmids. The culture medium of the transfected 293T cells was collected at 90 h posttransfection (p.t.) and inoculated into the amniotic cavity of 9-day-old embryonated chicken eggs. A stock of the recombinant viruses was prepared as described previously (Muraki et al., 2007 . The nucleotide sequence of the rN11A virus M gene was determined to ensure that no unwanted mutations were present.
Plaque titration
The infectious titers of the recombinants were determined according to the procedure reported by Matrosovich et al. (2006) and Muraki et al. (2011) using True Blue TM substrate (KPL).
Radioimmunoprecipitation
HMV-II cells infected with recombinant viruses were pulselabeled with [ 35 S]methionine (ARC) (30 mCi/35 mm dish) for 20 min at 26 h postinfection (p.i.) in RPMI 1640 medium lacking methionine, and chased for the indicated periods. Cells were then disrupted in RIPA buffer (0.01 M Tris-HCl (pH 7.4), 0.15 M NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS) containing cocktail of protease inhibitors (Sigma-Aldrich Biotechnology) and immunoprecipitated with MAbs against HEF (J14), NP (H27) and M1 (L2), or anti-CM2 serum. The immunoprecipitates obtained were analyzed by SDS-PAGE on 17.5% gels containing 4 M urea, and processed for fluorography (Yokota et al., 1983) .
Peptide-N-glycosidase F (N-glycanase) treatment
The immunoprecipitated CM2 proteins were digested with Nglycanase (Roche) for 16 h at 37 1C as described previously , concentrated with Amicon Ultra-0.5 centrifugal filter unit (Millipore), and then analyzed by SDS-PAGE. The purified VLPs (see below) were incubated with N-glycanase in the presence of 0.4% NP-40, followed by immunoblotting.
Immunoblotting
Purified VLPs (see below), plasmid-transfected 293T cells, and recombinant virus-infected HMV-II cells were resolved by SDS-PAGE on 17.5% gels containing 4 M urea. After SDS-PAGE, immunoblotting was carried out as described previously using the MAbs against HEF (S16), NP (H31) and M1 (L2), and anti-CM2 serum. The proteins were detected by an enhanced chemiluminescence Western blotting system (GE Healthcare) according to the manufacturer's instructions. Band intensities were measured by ImageJ software, version 1.42 (Rasband, W., National Institutes of Health /http://rsb.info.nih.gov/ij/S).
Indirect immunofluorescence
HMV-II cells grown on glass coverslips were infected with rWT or rN11A, and incubated at 33 1C. The cells were fixed in 10% formalin, permeabilized with 0.2% Triton X-100, and analyzed by indirect immunofluorescence with anti-CM2 serum (primary antibody) and fluorescein isothiocyanate (FITC)-conjugated antirabbit IgG (secondary antibody) (Vector). The trans-Golgi network was stained with anti-g-adaptin MAb (100/3) (Sigma) and Alexa Fluor 594 anti-mouse IgG (Molecular Probes). The cells were examined by an LSM710 confocal laser scanning microscope (Carl Zeiss).
Detection of cell surface proteins
To detect virus proteins expressed on the infected cells, cell surface biotinylation was performed as described previously (Muraki and Hay, 2009 ). Briefly, monolayered HMV-II cells infected with the recombinants were washed with ice-cold PBS at 26 h p.i., and exposed to 0.5 mg/ml sulfo-NHS-LC-biotin (Pierce) in PBS for 30 min on ice. The reaction was stopped by rinsing the cells twice with 100 mM glycine in ice-cold PBS, and the cells were lysed in 450 ml of RIPA buffer containing cocktail of protease inhibitors and incubated for 30 min on ice. The resulting lysates were centrifuged at 13,000 Â g for 20 min at 4 1C. The supernatants (420 ml) were incubated for 60 min at room temperature with streptavidin-agarose (Pierce). The obtained precipitates (biotinylated proteins) and whole cell lysates (30 ml) were subjected to SDS-PAGE, followed by immunoblotting.
Flow cytometry of HMV-II cells infected with viruses and VLPs
Monolayered HMV-II cells were trypsinized using Accutase (Sigma-Aldrich) and then added to the amniotic fluids containing recombinant viruses or the supernatants containing VLPs. After incubation on ice for 30 min, an aliquot of the cells was transferred to 33 1C and incubated for 120 min. The cells were then washed twice with Hanks' balanced salt solution and incubated with anti-HEF MAb J14 (primary antibody) and FITC-conjugated anti-mouse IgG antibody (secondary antibody) (Jackson Immunoresearch). The cells were subjected to flow cytometry using a FACSCalibur instrument (Becton Dickinson).
Generation and purification of VLPs
To generate WT-VLPs, 293T cells were transfected with the pPolI/NP-AA.GFP( À) and the nine expressing plasmids described above. For the generation of VLPs possessing non-glycosylated CM2 (N11A-VLPs), 293T cells were transfected with the same combination of plasmids, with the exception of the use of pME18S/Met-CM2-N11A instead of pME18S/Met-CM2-YA. To generate CM2-deficient VLPs (DCM2-VLPs), pME18S was transfected instead of pME18S/Met-CM2-YA. The VLPs in the culture medium were collected, purified and suspended in 10% glycerol in PBS as described previously . To generate VLPs containing luciferase (Luc)-vRNA, pPolI/NP-AA.Luc(À ) was transfected instead of pPolI/NP-AA.GFP(À ). Prior to the experiments, we re-evaluated the amount of the pME18S/Met-CM2-YA for transfection, and as a result the amount was determined to be 0.0315 mg per a 35-mm dish for the generation of WT-VLPs (see results).
Infection of HMV-II cells with VLPs
The purified VLPs were treated with N-tosyl-L-phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (20 mg/ml) at 37 1C for 10 min, followed by the addition of soybean trypsin inhibitor. The monolayered HMV-II cells were infected with the VLPs at 33 1C for 60 min and subsequently infected with the helper virus (AA/50) at a multiplicity of infection (MOI) of 5, and incubated for the indicated periods. For the quantification of incoming GFP-vRNA, the helper virus was not used for infection to avoid the replication of GFP-vRNA in the infected cells. GFP-positive HMV-II cells were observed under a fluorescent microscope (Olympus IX70) and photographed. Luciferase (Luc) activity in the VLPinfected cells was measured using a GloMax 96 Microplate Luminometer (Promega).
RNA extraction, reverse transcription, and real-time PCR
The RNAs were extracted from the plasmid-transfected 293T cells, purified VLPs, and nuclear and cytoplasmic fractions of VLPinfected HMV-II cells (see below) using an RNeasy Mini Kit (Qiagen). The RNA preparation was treated with DNase I (Takara), cleaned, and then reverse transcribed using a primer for the GFP gene (5 0 -ATGGTGAGCAAGGGCGAGGAGCTGTTC-3 0 ). Quantification of GFP-vRNA by real-time PCR was carried out using Power SYBR Green PCR Master Mix Kit (Applied Biosystems) in an ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems). The standard curve was calculated based on the results using a series of 10-fold dilutions of pPolI/NP-AA.GFP( À ) as a template.
As a loading control of RNAs extracted from the cells, b-actin mRNA was quantified by real-time PCR as described previously .
Cell fractionation
VLP-infected HMV-II cells were subjected to fractionation as described previously Sugawara et al., 2006) . Briefly, HMV-II cells mildly solubilized with RSB buffer (10 mM Tris-HCl, 100 mM NaCl, 1.5 mM MgCl 2 , pH 8.0) containing 0.3% NP-40 for 30 min at 0 1C were divided into two fractions by centrifugation at 1200 Â g for 5 min at 4 1C. The precipitate was washed twice with the RSB buffer containing 0.3% NP-40 and then used as the nuclear fraction. The supernatant was re-centrifuged at 10,000 Â g for 5 min at 4 1C, and the resulting supernatant was used as the cytoplasmic fraction.
Statistical analysis
All functional tests were carried out independently at least three times. Data between groups were analyzed using a paired t-test. A p value of less than 0.05 was considered statistically significant.
